They differ from FHH based on the clinical pattern of urinary hypocalciuria (as opposed to normal or hypercalciuria in MEN1) and the risk of endocrine malignancy with MEN1 mutations. The gene discussed is MEN1; the disease is familial hypocalciuric hypercalcemia.